Efficacy and safety of methylphenidate on attention deficit hyperactivity disorder in children with Down syndrome.
Down syndrome
attention deficit hyperactivity disorder
autism spectrum disorder
methylphenidate
oppositional deficit disorder
trisomy 21
Journal
Journal of intellectual disability research : JIDR
ISSN: 1365-2788
Titre abrégé: J Intellect Disabil Res
Pays: England
ID NLM: 9206090
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
revised:
14
02
2021
received:
26
01
2020
accepted:
21
02
2021
pubmed:
22
4
2021
medline:
15
12
2021
entrez:
21
4
2021
Statut:
ppublish
Résumé
Attention deficit hyperactivity disorder (ADHD) is a common co-morbidity that affects up to 44% of children with Down syndrome (DS). There is a need for reliable, good quality research on the use of methylphenidate within this population. The objective of this study is to report our experience regarding the management of ADHD in these children using methylphenidate. This study is a retrospective observation of 21 children with DS, followed at Jérôme Lejeune Institute between 2000 and 2018. The diagnosis of ADHD was made using the Diagnostic and Statistical Manual of Mental Disorders criteria. Efficacy was measured as response or non-response on two main symptoms: attention/concentration and hyperactivity/impulsivity. Safety was evaluated by the presence or absence of side effects. Sixteen out of the 21 children (76%) showed improvement with methylphenidate. The average age of treatment onset in responding children was 8 years and 10 months versus 6 years and 3 months in non-responders (P = 0.05). Average dose/weight was significantly different in responders and non-responders (0.82 vs. 0.54 mg/kg/day, respectively; P = 0.03). Twelve children out of 21 (57%) experienced side effects; only three experienced side effects severe enough to require treatment interruption. Most common side effects were loss of appetite and difficulties in falling asleep. Methylphenidate was effective and safe in treating ADHD in 76% of cases in children with DS, with few serious side effects to report. Early diagnosis of ADHD is important to improve the quality of life, learning, inclusion and socialisation of children with DS.
Sections du résumé
BACKGROUND
Attention deficit hyperactivity disorder (ADHD) is a common co-morbidity that affects up to 44% of children with Down syndrome (DS). There is a need for reliable, good quality research on the use of methylphenidate within this population. The objective of this study is to report our experience regarding the management of ADHD in these children using methylphenidate.
METHODS
This study is a retrospective observation of 21 children with DS, followed at Jérôme Lejeune Institute between 2000 and 2018. The diagnosis of ADHD was made using the Diagnostic and Statistical Manual of Mental Disorders criteria. Efficacy was measured as response or non-response on two main symptoms: attention/concentration and hyperactivity/impulsivity. Safety was evaluated by the presence or absence of side effects.
RESULTS
Sixteen out of the 21 children (76%) showed improvement with methylphenidate. The average age of treatment onset in responding children was 8 years and 10 months versus 6 years and 3 months in non-responders (P = 0.05). Average dose/weight was significantly different in responders and non-responders (0.82 vs. 0.54 mg/kg/day, respectively; P = 0.03). Twelve children out of 21 (57%) experienced side effects; only three experienced side effects severe enough to require treatment interruption. Most common side effects were loss of appetite and difficulties in falling asleep.
CONCLUSION
Methylphenidate was effective and safe in treating ADHD in 76% of cases in children with DS, with few serious side effects to report. Early diagnosis of ADHD is important to improve the quality of life, learning, inclusion and socialisation of children with DS.
Substances chimiques
Central Nervous System Stimulants
0
Methylphenidate
207ZZ9QZ49
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
795-800Informations de copyright
© 2021 MENCAP and International Association of the Scientific Study of Intellectual and Developmental Disabilities and John Wiley & Sons Ltd.
Références
Al-Khudairi R., Perera B., Solomou S. & Courtenay K. (2019) Adults with intellectual disability and ADHD: clinical characteristics and medication profiles. British Journal of Learning Disabilities, 1-8.
ANSM (2017) Méthylphénidate: données d'utilisation et de sécurité d'emploi en France 2017, p. 26.
Arnsten A. F. T. & Pliszka S. R. (2011) Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit/hyperactivity disorder and related disorders. Pharmacology, Biochemistry, and Behavior 99, 211-216.
American Psychiatric Association (2005) DMS IV - Manuel diagnostique et statistique des troubles mentaux. Paris: Elsevier Masson.
American Psychiatric Association (2015) DSM V - Manuel diagnostique et statistique des troubles mentaux. Paris: Elsevier Masson.
BMJ Publishing Group Ltd, Royal College of Psychiatrists and British Psychological Society (2013) Methylphenidate reduces ADHD symptoms in children with severe ADHD and intellectual disability. Evidence-Based Mental Health 16, 104.
Capone G., Goyal P., Ares W. & Lannigan E. (2006) Neurobehavioral disorders in children, adolescents, and young adults with Down syndrome. American Journal of Medical Genetics Part C: Seminars in Medical Genetics 142C, 158-172.
Capone G. T., Brecher L. & Bay M. (2016) Guanfacine use in children with Down syndrome and comorbid attention-deficit hyperactivity disorder (ADHD) with disruptive behaviors. Journal of Child Neurology 31, 957-964.
Ekstein S., Glick B., Weill M., Kay B. & Berger I. (2011) Down syndrome and attention-deficit/hyperactivity disorder (ADHD). Journal of Child Neurology 26, 1290-1295.
Golubchik P. & Weizman A. (2018) The effect of methylphenidate treatment on suspiciousness in children with ADHD alone or comorbid with ODD. International Journal of Psychiatry in Clinical Practice 22, 109-114.
Haute Autorité de Santé (n.d.) INTUNIV (guanfacine), agoniste alpha adrénergique. Available at: https://www.has-sante.fr/portail/jcms/c_2769369/fr/intuniv-guanfacine-agoniste-alpha-adrenergique (retrieved 20 January 2019).
Klassen A. F., Miller A. & Fine S. (2004) Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder. Pediatrics 114, e541-e547.
Maris M., Verhulst S., Wojciechowski M., Van de Heyning P. & Boudewyns A. (2016) Prevalence of obstructive sleep apnea in children with Down syndrome. Sleep 39, 699-704.
Mégarbané A., Noguier F., Stora S., Manchon L., Mircher C., Bruno R. et al. (2013) The intellectual disability of trisomy 21: differences in gene expression in a case series of patients with lower and higher IQ. European Journal of Human Genetics 21, 1253-1259.
National Institute for Health and Care Excellence (2018a) Attention deficit hyperactivity disorder (update). [C] Evidence reviews for pharmacological efficacy and sequencing pharmacological treatment. NICE guideline NG87. Intervention evidence review.
National Institute for Health and Care Excellence (2018b) Attention deficit hyperactivity disorder (update). [D] Evidence review for safety of pharmacological treatment. NICE guideline NG87. Intervention evidence review.
Oxelgren U. W., Myrelid Å., Annerén G., Ekstam B., Göransson C., Holmbom A. et al. (2017) Prevalence of autism and attention-deficit-hyperactivity disorder in Down syndrome: a population-based study. Developmental Medicine and Child Neurology 59, 276-283.
Palumbo M. L. & McDougle C. J. (2018) Pharmacotherapy of Down syndrome. Expert Opinion on Pharmacotherapy 19, 1875-1889.
Pearson D. A., Santos C. W., Roache J. D., Casat C. D., Loveland K. A., Lachar D. et al. (2003) Treatment effects of methylphenidate on behavioral adjustment in children with mental retardation and ADHD. Journal of the American Academy of Child and Adolescent Psychiatry 42, 209-216.
Perera B. (2018) Attention deficit hyperactivity disorder in people with intellectual disability. Irish Journal of Psychological Medicine 35, 213-219.
Prince J. (2008) Catecholamine dysfunction in attention-deficit/hyperactivity disorder: an update. Journal of Clinical Psychopharmacology 28, S39-S45.
Shaw P., Eckstrand K., Sharp W., Blumenthal J., Lerch J. P., Greenstein D. E. et al. (2007) Attention-deficit/hyperactivity disorder is characterized by a delay in cortical maturation. Proceedings of the National Academy of Sciences of the United States of America 104, 19649-19654.
Storebø O. J., Krogh H. B., Ramstad E., Moreira-Maia C. R., Holmskov M., Skoog M. et al. (2015) Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials. BMJ 351, h5203.
Sturman N., Deckx L. & van Driel M. L. (2017) Methylphenidate for children and adolescents with autism spectrum disorder. The Cochrane Database of Systematic Reviews 11, CD011144.
Zametkin A. J. & Rapoport J. L. (1987) Neurobiology of attention deficit disorder with hyperactivity: where have we come in 50 years? Journal of the American Academy of Child and Adolescent Psychiatry 26, 676-686.